首页> 美国卫生研究院文献>Scientific Reports >In Silico Exploration for Novel Type-I Inhibitors of Tie-2/TEK: The Performance of Different Selection Strategy in Selecting Virtual Screening Candidates
【2h】

In Silico Exploration for Novel Type-I Inhibitors of Tie-2/TEK: The Performance of Different Selection Strategy in Selecting Virtual Screening Candidates

机译:在Tie-2 / TEK新型I型抑制剂的计算机探索中:选择虚拟筛选候选对象时不同选择策略的性能

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The receptor tyrosine kinase Tie-2 is involved in vessel remodeling and maturation, and has been regarded as a potential target for the treatment of various solid tumors. The absence of novel, potent and selective inhibitors severely hampers the understanding of the therapeutic potential of Tie-2. In the present work, we describe the discovery of novel type-I inhibitors of Tie-2 by structure-based virtual screening. Preliminary SAR was also performed based on one active compound, and several novel inhibitors with low micro-molar affinity were discovered. To directly compare the efficiency between different filtering strategies in selecting VS candidates, two methods were separately carried out to screen the same chemical library, and the selected VS candidates were then experimentally assessed by in vitro enzymatic assays. The results demonstrate that the hit rate is improved when stricter drug-likeness criteria and less number of molecules for clustering analysis are used, and meanwhile, the molecular diversity of the compounds still maintains. As a case study of TIE-2, the information presented in this work underscores the importance of selecting an appropriate selection strategy in VS campaign, and the novel inhibitors identified and the detailed binding modes of action provide a starting point for further hit-to-lead optimization process.
机译:受体酪氨酸激酶Tie-2参与血管重塑和成熟,并且已被认为是治疗各种实体瘤的潜在靶标。缺乏新型,有效和选择性抑制剂会严重妨碍对Tie-2治疗潜力的理解。在本工作中,我们描述了通过基于结构的虚拟筛选发现Tie-2的新型I型抑制剂。还基于一种活性化合物进行了初步SAR,并发现了几种具有低微摩尔亲和力的新型抑制剂。为了直接比较选择VS候选物的不同过滤策略之间的效率,分别进行了两种方法来筛选相同的化学文库,然后通过体外酶促实验对所选的VS候选物进行实验评估。结果表明,使用更严格的药物相似性标准和较少的用于聚类分析的分子数量,可以提高命中率,同时仍保持化合物的分子多样性。作为TIE-2的案例研究,本文提供的信息强调了在VS战役中选择合适的选择策略的重要性,并且鉴定出的新型抑制剂和详细的结合作用方式为进一步的击中目标提供了起点。引导优化过程。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号